ReviewJournal of hematology & oncology2012
Novel CD20 monoclonal antibodies for lymphoma therapy.
Review in Journal of hematology & oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20Scientific reports · 2021Pooled it
- Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.International journal of hematology · 2017Pooled it
- A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.Clinical immunology (Orlando, Fla.) · 2014Trial
- Why antibody isotype matters for immunotherapy.Antibody therapeutics · 2026Review
- Exploiting signal transduction pathways for cancer therapy: insights from natural products in preclinical models.Frontiers in pharmacology · 2026Review
- Current Status of Molecularly Targeted Therapeutics in Blood Cancers.International journal of molecular sciences · 2025Review
- Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells.Biochemistry and biophysics reports · 2025Article
- Autoimmune bullous diseases: pathogenesis and clinical management.Molecular biomedicine · 2025Review
- Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.American journal of hematology · 2025Review
- Development of Hemispherical 3D Models of Human Brain and B Cell Lymphomas Using On-Chip Cell Dome System.Bioengineering (Basel, Switzerland) · 2024Article
- IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients.BMC immunology · 2024Observational
- Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice.Cancers · 2023Review
- Review
- Modeling and affinity maturation of an anti-CD20 nanobody: a comprehensive in-silico investigation.Scientific reports · 2023Article
- Computational and Experimental Evaluation of Linker Peptides and Thioredoxin Fusion Tag in CD20-rituximab Specific Interactions.Iranian journal of pharmaceutical research : IJPR · 2022Article
- Pemphigus Vulgaris: Present and Future Therapeutic Strategies.Dermatology practical & conceptual · 2022Review
- Immunotherapy in indolent Non-Hodgkin's Lymphoma.Leukemia research reports · 2022Article
- Immunomodulatory Treatment Strategies Targeting B Cells for Heart Failure.Frontiers in pharmacology · 2022Review
- Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies.Paediatric drugs · 2021Review
- Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab.BMJ case reports · 2021Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin's lymphoma (NHL). Novel agents are under active clinical trials. This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.